IQVIA Holdings (NYSE:IQV) reported strong Q3 2021 results as the life sciences analytics and clinical research company more than doubled its net income year-over-year.
Net income increased ~142% to $261M buoyed especially by the research and development solution segment.
That business saw revenues increase 32.4% to ~$1.9B.
The technology and analytics solutions segments saw revenues rise 10.8% to ~1.3B.
Contracts sales and medical solutions grew 12.3% to $201M.